Skip to main content
OpenTrials
Completed

NCT Number: NCT05184387

A Prospective Epidemiological Cohort Study Evaluating Occurrences of Influenza-like Illness.

This Prospective epidemiological cohort study is being conducted in order to generate epidemiological data in support of Osivax's clinical development of a broad spectrum influenza vaccine based upon the internal influenza nucleoprotein (NP) as a target for immune response.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Influenza Infections Influenza, Human Orthomyxoviridae Infections RNA Virus Infections Respiratory Tract Diseases Respiratory Tract Infections Virus Diseases

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Centre for Vaccinology (CEVAC)

Ghent, 9000, Belgium

About this study

The present study is being conducted in order to generate epidemiological data in support of Osivax's clinical development of a broad spectrum influenza vaccine based upon the internal influenza nucleoprotein (NP) as a target for immune response.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Written informed consent.
  • Healthy male or female subjects, as determined by medical history and medical examination (as needed).
  • Between the ages of 18 and 55 years, inclusive.
  • Subject who has fully been vaccinated with licensed severe Acute Respiratory Syndrome SARS-CoV-2 (COVID-19) vaccine(s) according to national recommendations for the corresponding population group.
  • Reliable and willing to make themselves available for the duration of the study, and willing and able to follow study procedures.
  • Ability and technical possibility for completing an electronic Diary (eDiary) and electronic Flu-PRO® questionnaire (ePRO).

Exclusion criteria

  • Previous influenza vaccination within 6 months before the day of enrollment or planned to receive during the study duration.
  • Any known or suspected immunodeficient conditions.
  • Current history of significant uncontrolled medical illness such as diabetes, hypertension, heart, renal or hepatic diseases, as judged by the Investigator.
  • Known infection with human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis B virus (HBV) to the subject's knowledge.
  • Administration of any investigational or non-registered drug or vaccine within 3 months prior to enrollment, or planned administration of any such product during the whole study period.
  • History of receiving blood, blood components or immunoglobulins within 3 months prior to the day of enrollment, or planned to receive such product during the whole study period.
  • Behavioral or cognitive impairment, or psychiatric disease that, in the opinion of the Investigator, may interfere with the subject's ability to participate in the study.
  • Past (stopped less than 6 months before enrolment) or current history of alcohol or drug abuse, or current smoking habit above 10 cigarettes per day, or current vaping.
  • Treatment that can affect immune response such as systemic or high dose inhaled corticosteroids (>800μg/day beclomethasone or equivalent; occasional inhaled corticosteroids for asthma therapy are allowed), radiation treatment, cytotoxic drugs, or current or recent (within 30 days before study entry) chronic or prolonged (>10 days) use of systemic non-steroidal antiinflammatory drugs, interferon, immunomodulators, allergy shots, as judged by the Investigator.
  • Individuals with history of any illness that, in the opinion of the Investigator, might interfere with the results of the study or pose additional risk to the subjects due to participation in the study.

Treatment and study plan

Blood Samples

Other

Collection of blood samples and completion of an electronic Diary (eDiary)

Primary outcomes

  1. Proportion of overall subjects reporting Influenza-Like-Illness cases as per Flu-PRO® questionnaire.

    Time frame: Through study completion, an average of 8 months.

  2. Proportion of subjects reporting Influenza-Like-Illness cases as per Flu-PRO® questionnaire with laboratory-confirmed influenza.

    Time frame: Through study completion, an average of 8 months.

  3. Proportion of subjects reporting Influenza-Like-Illness cases as per Flu-PRO® questionnaire with non-laboratory-confirmed influenza.

    Time frame: Through study completion, an average of 8 months.

  4. Severity scores of overall Influenza-Like-Illness cases as per Flu-PRO® questionnaire.

    Time frame: Through study completion, an average of 8 months.

  5. Severity scores of Influenza-Like-Illness cases as per Flu-PRO® questionnaire with laboratory-confirmed influenza.

    Time frame: Through study completion, an average of 8 months.

  6. Severity scores of Influenza-Like-Illness cases as per Flu-PRO® questionnaire with non-laboratory-confirmed influenza.

    Time frame: Through study completion, an average of 8 months.

  7. Duration of overall Influenza-Like-Illness cases as per Flu-PRO® questionnaire.

    Time frame: Through study completion, an average of 8 months.

  8. Duration of Influenza-Like-Illness cases as per Flu-PRO® questionnaire with laboratory-confirmed influenza.

    Time frame: Through study completion, an average of 8 months.

  9. Duration of Influenza-Like-Illness cases as per Flu-PRO® questionnaire with non-laboratory-confirmed influenza.

    Time frame: Through study completion, an average of 8 months.

  10. Anti-NP immunoglobulin G (IgG) titers by ELISA at each time point.

    Time frame: Through study completion, an average of 8 months.

  11. Symptomatic and asymptomatic flu cases based on the abovementioned variables/parameters.

    Time frame: Through study completion, an average of 8 months.

Sponsors and collaborators

Lead sponsor

Osivax

Industry

Collaborators

  • University Ghent

Registry information

Official study title

A Prospective Epidemiological Cohort Study Evaluating Occurrences of Influenza-like Illness in an Urban and Suburban Population of Healthy Subjects Aged 18-55 Years, Not Vaccinated Against Influenza.

Important dates

Study start
2021
Primary completion
2022
Study completion
2022
First posted
Jan 11, 2022
Registry last updated
Jul 19, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.